The EEF1D Knockout HGC-27 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HGC-27 human gastric carcinoma cell line, designed to disrupt the EEF1D gene and ablate its encoded elongation factor 1-delta (eEF1D) protein. This loss-of-function model provides a powerful tool for investigating the role of translation elongation control in gastric cancer. As a polyclonal pool, this product reflects a heterogeneous knockout population, enabling studies that mirror natural genetic variability while avoiding artifacts associated with single-cell cloning. The cells are delivered as a ready-to-use population for functional genomics, signaling pathway analysis, and drug discovery applications focused on protein synthesis-dependent oncogenic mechanisms.
HGC-27 is a widely employed cell line established from the lymph node metastasis of a poorly differentiated gastric adenocarcinoma, characterized by aggressive growth, invasive behavior, and metastatic propensity. Its origin from a metastatic site renders the line particularly relevant for studying advanced gastric cancer, where dysregulated translation facilitates rapid proliferation, survival, and dissemination. The epithelial nature of HGC-27 cells offers a physiologically appropriate context for dissecting the molecular underpinnings of gastric adenocarcinoma, including the interplay between translation control and epithelial-mesenchymal transition. This background makes the EEF1D knockout a relevant model for translational oncology research.
EEF1D encodes the delta subunit of the eEF1 complex and functions as a guanine nucleotide exchange factor (GEF) for eEF1A. It catalyzes the exchange of GDP for GTP on eEF1A, which is essential for the delivery of aminoacyl-tRNAs to the ribosome during translation elongation. The activity of EEF1D is regulated by several upstream kinases, including mTOR, CK2, PKC, and MNK1, linking it directly to growth factor and nutrient-sensing pathways. Upon activation, eEF1D promotes eEF1A-mediated global protein synthesis and selectively enhances translation of oncogenic mRNAs such as c-Myc and Bcl-2. EEF1D physically interacts with multiple components of the translation machinery, including eEF1A, eEF1B2, eEF1G, and valyl-tRNA synthetase (VARS), and has been reported to associate with p53, suggesting crosstalk with apoptotic signaling.
Disruption of EEF1D in HGC-27 cells is expected to impair GDP/GTP exchange on eEF1A, leading to attenuated translation elongation and reduced protein synthesis, with particular impact on rapidly dividing cancer cells that rely on high translational output to sustain oncogenic programs. This model enables dissection of how the mTOR-eEF1D-eEF1A axis contributes to gastric cancer progression, including cell proliferation, resistance to apoptosis, and regulation of the actin cytoskeleton. Given the involvement of EEF1D in integrated stress response and eIF2?? signaling, the knockout may modulate cellular adaptation to nutrient deprivation and therapeutic stress, providing a platform to examine synthetic lethal relationships with agents that target the translational machinery.
Researchers can employ the EEF1D Knockout HGC-27 Polyclonal Cells in a wide range of experimental paradigms, including investigation of translation elongation control mechanisms, identification of EEF1D-dependent protein synthesis signatures via polysome profiling or puromycin incorporation assays, and screening for synthetic lethal interactions with translation inhibitors such as mTOR or MNK1 inhibitors. The model is also suitable for studying resistance mechanisms to mTOR-targeted therapies, exploring the role of translation in epithelial-mesenchymal transition, and performing co-immunoprecipitation to validate altered protein-protein interactions. Typical readouts include western blotting for EEF1D, eEF1A, and phospho-eEF2; RT-qPCR for stress response genes (ATF4, CHOP); MTT and colony formation assays; annexin V apoptosis analysis; and global transcriptomic profiling using RNA-seq. For further technical specifications or to discuss custom experimental applications, please contact Ascent Research.
